刘乾文，男，福建上杭人。中山大学肿瘤医院胸外科主治医师。 一、学习及工作经历： 2000年—2006年：中国医科大学临床医学外语系（六年制）学习 2006年—2009年：北京大学人民医院外科学硕士研究生 2009年—2013年：中山大学附属肿瘤医院胸外科住院医师 2012年至今：在职博士研究生 2014年至今：中山大学附属肿瘤医院胸外科主治医师 二、文章及著作（近三年发表论文） 1.Liu Q, Tan Z, Lin P, Long H, Zhang L, Rong T, Meng Y, Ma G: Impact of the number of resected lymph nodes on postoperative survival of patients with node-negative oesophageal squamous cell carcinoma, European journal of cardio-thoracic surgery 2013, 44 (4): 631-636. 2.Liu QW, Fu JH, Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E: Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma, Diseases of the esophagus 2011, 24, 374–380. 3.Qianwen Liu, Guowei Ma, Haoxian Yang, Jing Wen, Mei Li, Hong Yang, Kongjia Luo, Yi Hu, Jianhua Fu: Lack of EGFR gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung, Thoracic Cancer 2013, 5 (1), 63-67. 4.Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P, Fu JH: Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China, The Annals of thoracic surgery 2012, 93:1861-1866. 5.Liang Zhang, Wei Ou, Qianwen Liu, Ning Li, Li Liu and Siyu Wang: Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer, Thoracic Cancer 2013, 5 (1), 50-56. 6.Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, Wang SY: A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma, Cancer 2014, 10.1002/cncr.28591. 7.Meng, Y. Q., Cao, X., Wen, Z. S., Liu, Q. W., Tan, Z. H., Duan, H., Ma, G. W., Lin, P.: Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma, Diseases of the esophagus 2013, 10.1111/dote.12128. 三、获奖情况 2013年度中山大学肿瘤医院普通话教学比赛三等奖